Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2020–2027

A10599
Pages: 168
Mar 2021 | 254 Views
 
Author(s) : Sayali Shinde, Smita Nerkar , Onkar Sumant
Tables: 101
Charts: 16
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Rapid Acting Insulin Market

Request Now !

The global rapid acting insulin market size was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. 

Patients with different health issues such as respiratory disease and diabetes are at higher risk of getting affected by this covid-19 virus. It is found that the mortality rate is high in a patient with diabetes compared to the general population. Without or irregular supply of rapid acting insulin a person with diabetes will die within a few days. To overcome this situation the insulin manufacturing companies are taking different steps to make the product available to the patients, which drives the market growth in near future. On the side, there is no supply shortage of rapid acting insulin but the use of insulin is get reduced.

Rapid acting insulin is one of the fastest acting insulin that starts working within 15 minutes of its introduction. Action of this insulin is supposed to last for 5 hours. Some of the rapid acting insulin available in the market are Humalog, Fiasp, NovoRapid, Apidra and others. 

Rapid-Acting-Insulin-Market,-2020-2027

Get more information on this report : Request Sample Pages

The COVID-19 outbreak that started from Wuhan city of China has now wide spread globally. Almost every nation is dealing with the outbreak. Furthermore, most of the markets have observed a drop down, owing to the lockdown situation declared by the government of various countries. However, the outbreak of COVID-19 is expected to contribute to the growth opportunities for industries wherein the treatment and management of chronic conditions are carried out. According to an article by the American Diabetes Association in 2020, people with diabetes are more likely to have serious complications from COVID-19. Furthermore, having heart disease or other complications in addition to diabetes could worsen the chance of getting seriously ill from COVID-19 as more than one condition makes it harder for patients to fight the infection. This helped major players to adopt various strategies to gain maximum share during the COVID-19 outbreak. For instance, in April 2020, in response to the emergency caused by COVID-19, Eli Lilly and Company introduced the Lilly Insulin Value Program. This program allows anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lilly insulin for $35. Furthermore, the program became effective from the given date and covered most Lilly insulin, including all Humalog (insulin lispro injection 100 units/mL) formulations. On the side, there is no supply shortage of rapid acting insulin.

The growth of the global rapid acting insulin market is majorly driven by the surge in prevalence of diabetes worldwide, increase in investment in research and development (R&D) for human recombinant insulin is expected to drive the need for insulin used in management of diabetes thereby boosting the growth of the market. Furthermore, sedentary & unhealthy lifestyles double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes. However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population in developing regions are expected to provide lucrative growth opportunities for the rapid acting insulin market growth.

The global rapid acting insulin market is segmented on the basis of product type, indication, distribution channel, and region. By product type, the market is segregated into insulin lispro, insulin aspart, and insulin glulisine. Depending on indication, it is fragmented into type 1 diabetes and type 2 diabetes. Furthermore, the market is divided on the basis of distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segmental review

By product type, the insulin lispro segment is anticipated to grow with the largest rapid acting insulin market share over the forecast period. This is attributed to better advantages posed by the product, which include faster subcutaneous absorption, earlier & greater insulin peak, and shorter duration of action. This contributes to help the industry generate higher revenue through insulin lispro.

Rapid Acting Insulin Market
By Product Type

Your browser does not support the canvas element.

Insulin Lispro is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By indication, the type 2 diabetes segment occupied the largest share of the market, owing to rise in urbanization, unhealthy diet, and reduced physical activity leads to rise in the number of people with type 2 diabetes which will further boost the rapid acting insulin market growth.

Rapid Acting Insulin Market
By Indication

Your browser does not support the canvas element.

Type 2 Diabetes holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By distribution channel, the drug stores & retail pharmacies segment occupied the largest share of the market, owing to availability of drug store & retail pharmacy stores everywhere. In addition these pharmacies provide alternate options for insulin, if the ones prescribed are not available. 

Rapid Acting Insulin Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 4.1% during 2020-2027.

Get more information on this report : Request Sample Pages

North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027 due to increasing incidences of diabetes and geriatric population, thereby driving the region’s rapid acting insulin market. On the other side, Asia-Pacific is expected to register the highest CAGR in the rapid acting insulin market in future, owing to westernized lifestyle behaviors and the increased prevalence of obesity. This is expected to boost the rapid acting insulin market over the forecast period.

Some of the key players operating in the rapid acting insulin market include ADOCIA SAS, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Geropharm LLC, Mannkind Corporation, Novo Nordisk A/S, Sanofi S.A., and Wockhadt Ltd.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global rapid acting insulin market trends from 2020 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The rapid acting insulin market forecast is studied from 2020 to 2027.
  • The rapid acting insulin market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global rapid acting insulin market.

Key Market Segments

By Product Type

  • Insulin Lispr
  • Insulin Aspart 
  • Insulin Glulisine 

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East & Africa
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
1.3.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019

3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Sedentary and unhealthy lifestyle
3.5.1.2.Increased availability of continuous glucose monitoring
3.5.1.3.Increasing investment in research and development (R&D) for human recombinant insulin
3.5.1.4.Increase in government expenditure on healthcare

3.5.2.Restraints

3.5.2.1.Adverse effects associated with the use of rapid acting insulin

3.5.3.Opportunities

3.5.3.1.Untapped opportunities and undiagnosed population in developing regions

3.5.4.Impact analysis

3.6.COVID-19 Impact Analysis On Rapid Acting Insulin Market

CHAPTER 4:RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Lispro Insulin

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Aspart Insulin

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Glulisine Insulin

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:RAPID ACTING INSULIN  MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Type 1 Diabetes

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Type 2 Diabetes

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital Pharmacies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Drug Stores & retail pharmacies

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Online providers

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:RAPID ACTING INSULIN MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America rapid acting insulin market, by country

7.2.2.1.U.S.

7.2.2.1.1.Market size and forecast, by product
7.2.2.1.2.Market size and forecast, by indication
7.2.2.1.3.Market size and forecast, by distribution channel

7.2.2.2.Canada

7.2.2.2.1.Market size and forecast, by product
7.2.2.2.2.Market size and forecast, by indication
7.2.2.2.3.Market size and forecast, by distribution channel

7.2.2.3.Mexico

7.2.2.3.1.Market size and forecast, by type
7.2.2.3.2.Market size and forecast, by indication

7.2.2.3.3.Market size and forecast, by distribution channel

7.2.3.North America market size and forecast, type
7.2.4.North America market size and forecast, indication
7.2.5.North America market size and forecast, by distribution channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe rapid acting insulin market, by country

7.3.2.1.Germany

7.3.2.1.1.Market size and forecast, by type
7.3.2.1.2.Market size and forecast, by indication
7.3.2.1.3.Market size and forecast, by distribution channel

7.3.2.2.UK

7.3.2.2.1.Market size and forecast, by type
7.3.2.2.2.Market size and forecast, by indication
7.3.2.2.3.Market size and forecast, by distribution channel

7.3.2.3.France

7.3.2.3.1.Market size and forecast, by type
7.3.2.3.2.Market size and forecast, by indication
7.3.2.3.3.Market size and forecast, by distribution channel

7.3.2.4.Italy

7.3.2.4.1.Market size and forecast, by type
7.3.2.4.2.Market size and forecast, by indication
7.3.2.4.3.Market size and forecast, by distribution channel

7.3.2.5.Spain

7.3.2.5.1.Market size and forecast, by type
7.3.2.5.2.Market size and forecast, by indication
7.3.2.5.3.Market size and forecast, by distribution channel

7.3.2.6.Rest of Europe

7.3.2.6.1.Market size and forecast, by type
7.3.2.6.2.Market size and forecast, by indication
7.3.2.6.3.Market size and forecast, by distribution channel

7.3.3.Europe market size and forecast, type
7.3.4.Europe market size and forecast, indication
7.3.5.Europe market size and forecast, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Rapid acting insulin market, by country

7.4.2.1.China

7.4.2.1.1.Market size and forecast, by type
7.4.2.1.2.Market size and forecast, by indication
7.4.2.1.3.Market size and forecast, by distribution channel

7.4.2.2.Japan

7.4.2.2.1.Market size and forecast, by type
7.4.2.2.2.Market size and forecast, by indication
7.4.2.2.3.Market size and forecast, by distribution channel

7.4.2.3.Australia

7.4.2.3.1.Market size and forecast, by type
7.4.2.3.2.Market size and forecast, by indication
7.4.2.3.3.Market size and forecast, by distribution channel

7.4.2.4.India

7.4.2.4.1.Market size and forecast, by type
7.4.2.4.2.Market size and forecast, by indication
7.4.2.4.3.Market size and forecast, by distribution channel

7.4.2.5.Rest of Asia-Pacific

7.4.2.5.1.Market size and forecast, by type
7.4.2.5.2.Market size and forecast, by indication
7.4.2.5.3.Market size and forecast, by distribution channel

7.4.3.Asia-Pacific market size and forecast, by type
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by distribution channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA rapid acting insulin market, by country

7.5.2.1.Latin America

7.5.2.1.1.Market size and forecast, by type
7.5.2.1.2.Market size and forecast, by indication
7.5.2.1.3.Market size and forecast, by distribution channel

7.5.2.2.Middle East & Africa

7.5.2.2.1.Market size and forecast, by type
7.5.2.2.2.Market size and forecast, by indication
7.5.2.2.3.Market size and forecast, by distribution channel

7.5.3.LAMEA market size and forecast, by type
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.ADOCIA SAS

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.Biocon Limited

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.Eli Lilly And Company

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Gan & Lee Pharmaceuticals

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments

8.5.Geropharm LLC

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments

8.6.Mannkind Corporation

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Business performance

8.7.Novo Nordisk A/S

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segment
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.Sanofi S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segment
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Wockhadt Ltd.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance

LIST OF TABLES

TABLE 01.RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 02.RAPID ACTING INSULIN MARKET FOR LISPRO INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 03.RAPID ACTING INSULIN MARKET FOR ASPART INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 04.RAPID ACTING INSULIN MARKET FOR GLULISINE INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 05.RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 06.RAPID ACTING INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 07.RAPID ACTING INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 09.RAPID ACTING INSULIN MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 10.RAPID ACTING INSULIN MARKET FOR DRUG STORE & RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 11.RAPID ACTING INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.RAPID ACTING INSULIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 14.U.S. RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 15.U.S. RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 16.U.S. RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 17.CANADA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 18.CANADA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 19.CANADA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 20.MEXICO RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 21.MEXICO RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 22.MEXICO RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 26.EUROPE RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 27.GERMANY RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 28.GERMANY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.GERMANY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 30.UK RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 31.UK RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.UK RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.FRANCE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 34.FRANCE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 35.FRANCE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.ITALY RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 37.ITALY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.ITALY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 39.SPAIN RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 40.SPAIN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.SPAIN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 43.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 45.EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 46.EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 48.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 49.CHINA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 50.CHINA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.CHINA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 52.JAPAN RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.JAPAN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 54.JAPAN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 55.AUSTRALIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 56.AUSTRALIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.AUSTRALIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 58.INDIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 59.INDIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 60.INDIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION MARKET, 2019–2027 ($MILLION)
TABLE 67.LAMEA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 68.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 69.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 72.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 73.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 74.LAMEA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 75.LAMEA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 76.LAMEA RAPID ACTING INSULIN MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 01.ADOCIA: COMPANY SNAPSHOT
TABLE 02.ADOCIA: OPERATING SEGMENTS
TABLE 03.ADOCIA: PRODUCT PORTFOLIO
TABLE 04.BIOCON: COMPANY SNAPSHOT
TABLE 05.BIOCON: OPERATING SEGMENTS
TABLE 06.BIOCON: PRODUCT PORTFOLIO
TABLE 07.ELI LILLY: COMPANY SNAPSHOT
TABLE 08.ELI LILLY: OPERATING SEGMENTS
TABLE 09.ELI LILLY: PRODUCT PORTFOLIO
TABLE 10.GAN&LEE: COMPANY SNAPSHOT
TABLE 11.GAN&LEE: PRODUCT PORTFOLIO
TABLE 12.GEROPHARM: COMPANY SNAPSHOT
TABLE 13.GEROPHARM: OPERATING SEGMENTS
TABLE 14.GEROPHARM: PRODUCT PORTFOLIO
TABLE 15.MANNKIND: COMPANY SNAPSHOT
TABLE 16.MANNKIND: OPERATING SEGMENTS
TABLE 17.MANNKIND: PRODUCT PORTFOLIO
TABLE 18.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 19.NOVO NORDISK: OPERATING SEGMENTS
TABLE 20.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 21.SANOFI: COMPANY SNAPSHOT
TABLE 22.SANOFI: PRODUCT PORTFOLIO
TABLE 23.WOCKHARDT: COMPANY SNAPSHOT
TABLE 24.WOCKHARDT: OPERATING SEGMENTS
TABLE 25.WOCKHARDT: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL RAPID ACTING INSULIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2018–2021
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGANING POWER OF BUYERS
FIGURE 08.MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.HIGH COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR LISPRO INSULIN BY COUNTRY, 2019–2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ASPART INSULIN BY COUNTRY, 2019–2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR GLULISINE INSULIN BY COUNTRY, 2019–2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 1 DIABETES BY COUNTRY, 2019–2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 2 DIABETES BY COUNTRY, 2019–2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR HOSPITAL PHARMACY BY COUNTRY, 2019–2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR DRUG STORE & RETAIL PHARMACY BY COUNTRY, 2019–2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ONLINE PROVIDERS BY COUNTRY, 2019–2027 (%)
FIGURE 21.U.S. RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 22.CANADA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 23.MEXICO RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 24.GERMANY RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 25.UK RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 26.FRANCE RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 27.ITALY RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 28.SPAIN RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 29.REST OF EUROPE RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 30.CHINA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 31.JAPAN RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 32.AUSTRALIA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 33.INDIA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 34.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 35.LATIN AMERICA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 36.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, 2019–2027 ($MILLION)
FIGURE 01.ADOCIA: REVENUE, 2017–2019 ($MILLION)
FIGURE 02.BIOCON: REVENUE, 2018–2020 ($MILLION)
FIGURE 03.BIOCON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 04.BIOCON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 05.ELI LILLY: REVENUE, 2018–2019 ($MILLION)
FIGURE 06.ELI LILLY: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 07.ELI LILLY: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 08.MANNKIND: REVENUE, 2019–2020 ($MILLION)
FIGURE 09.NOVO NORDISK: REVENUE, 2018–2020 ($MILLION)
FIGURE 10.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 12.SANOFI: REVENUE, 2017–2019 ($MILLION)
FIGURE 13.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 14.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 15.WOCKHARDT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 16.WOCKHARDT: REVENUE SHARE BY REGION, 2019 (%)

 
 

In accordance to several interviews conducted, the rapid acting insulin market is expected to witness a significant growth owing to sedentary & unhealthy lifestyles increase all causes of mortality, double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes.

Furthermore, surge in prevalence of diabetes worldwide is the major factor that contributes toward growth of the rapid acting insulin market. In addition increase in government expenditure on healthcare also propel the market growth.

Increasing incidences of diabetes and geriatric population, are anticipated to drive the growth in North America On the other side, Asia-Pacific is expected to register the highest CAGR in the rapid acting insulin market in future, owing to westernized lifestyle behaviors and the increased prevalence of diabetes. This is expected to boost the rapid acting insulin market over the forecast period.

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Rapid Acting Insulin Market is $7,100.4million in 2019.

A. The forcast period for Rapid Acting Insulin Market is 2020 to 2027

A. The market value of Rapid Acting Insulin Market in 2020 is $6,736.9 million.

A. The base year is 2019 in Rapid Acting Insulin Market

A. Top companies such as, ADOCIA SAS, Biocon Limited, Eli Lilly And Company, Gan & Lee Pharmaceuticals, Geropharm LLC, Mannkind Corporation, Novo Nordisk A/S, Sanofi S.A., and Wockhadt Ltd. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in regions.

A. Lispro, product type segment is the most influencing segment, owing to the better advantages posed by the product, which includes faster subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action, which is driving the growth of the global Rapid acting insulin market

A. The major factor that fuels the growth of the rapid acting insulin market includes, the surge in the availability of continuous glucose monitoring. Furthermore, the sedentary, unhealthy lifestyle adapted by the population due to increase in working population would contribute to market growth. The family diabetic history, however is also a major factor causing the surge in demand for rapid acting insulin. In addition to this, the steep rise in the research and development in the human recombinant insulin would propel the growth of the market are expected to boost the market growth.

A. North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027, owing to increasing incidences of diabetes and geriatric population. However, Asia-Pacific is expected to grow at the highest CAGR, owing to favorable government policies and increasing R&D initiatives by key manufacturers.

A. Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. 

A. Rapid-acting insulin, is a type of synthetic (man-made) insulin which is injectable and is prescribed for people with diabetes to help control blood glucose (blood sugar) levels. It is absorbed into the bloodstream within minutes,to mimic the action of bolus insulin, the surge of insulin released by the pancreas in response to the ingestion of food.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Rapid Acting Insulin Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers